Introduction
Backed by an unprecedented knowledge of cancer genes (1), it is now possible to disable signaling mechanisms of tumor cells without affecting normal tissues using targeted therapy (2, 3) . As pioneered by the development of a small molecule antagonist of the BCR-ABL kinase, i.e., imatinib mesylate, targeted cancer therapy is feasible (2) , and has produced, in some cases, spectacular clinical responses (4) . However, the underlying concept of target-centric drug discovery based on high-throughput screening of potential druggable molecules has been difficult to generalize. Costly, laborintensive, and low-yield (typically one in a million hits reaches the market) (5) target-centric drug discovery has generated many hopeful agents that provided minimal or no gains when tested in the clinic (6, 7) . This high rate of failure may be due to the extreme heterogeneity of even seemingly identical tumors, carrying hundreds of mutated, amplified, or deregulated genes (8, 9) . Such complexity makes it difficult to identify a single, driving, signaling pathway suitable for therapeutic intervention, and raises concerns that an imatinib-like approach to drug discovery (4) may be feasible only in a handful of tumors (6) .
To overcome these barriers, efforts have begun to explore systems biology tools (10) to model cancer pathways as globally interconnected networks (11) . Such connectivity maps, linking together multiple signaling pathways (12) , may more faithfully recapitulate the tumor tactics responsible for treatment failure, including redundancy, buffering, and modularity into semiautonomous subnetworks (6) . This information can also be exploited for a novel pathway-oriented drug discovery (11) , with the goal of identifying inhibitors of nodal proteins (5), i.e., molecules that integrate multiple signaling subnetworks (6, 11) . The expectation is that such network inhibitors may be best suited to simultaneously disable multiple mechanisms of tumor maintenance instead of a single gene and thus overcome the genetic and molecular heterogeneity of progressive disease. The molecular chaperone Hsp90 is a cancer nodal protein (13) and a potentially ideal candidate for pathwayoriented drug discovery (14) . In concert with other chaperones, Hsp90 oversees fundamental mechanisms of protein folding quality control via sequential ATPase cycles (15) . A distinctive feature of this pathway is its compartmentalization in multiple, semiautonomous, subcellular networks. Accordingly, Hsp90-directed folding controls the stability of hosts of client proteins in the cytosol (15, 16) , disassembles transcriptional complexes in the nucleus (17) , regulates the early secretory pathway in the endoplasmic reticulum (18) , and mediates cell motility in the extracellular milieu (19) . Recent studies have expanded this paradigm to another subcellular compartment, the mitochondrion, in which Hsp90 and its related chaperone, TRAP-1 (20) , bind components of a permeability transition pore, notably cyclophilin D (CypD) (21) , and antagonize its opening, preserving organelle integrity and suppressing the initiation of cell death (22) .
To drug the Hsp90 networks in cancer (23) , several small molecule ATPase antagonists have been developed from the ansamycin antibiotic geldanamycin (GA) (14, 24) or, more recently, from purine or resorcinol structures (25) . Backed by encouraging preclinical studies, showing differential activity in tumor cells compared with normal tissues, Hsp90-based therapy has now reached the clinic. However, despite the expectation that these agents may function as genuine pathway inhibitors, their activity in cancer patients has been modest or not observed at all (26) .
In this study, we tested the impact of network subcellular compartmentalization in dictating the activity of Hsp90 inhibitors. We report the design of Gamitrinibs (GA mitochondrial matrix inhibitors), which are, to our knowledge, the first class of fully synthetic, combinatorial small molecules, targeting the Hsp90 network in tumor mitochondria (22) .
Results

Selective targeting of the mitochondrial Hsp90 network.
We began this study by designing what we believe to be a new class of small molecule Hsp90 antagonists selectively targeted to mitochondria, i.e., Gamitrinibs. The chemical synthesis of Gamitrinib is described in detail in the Supplemental Data and Supplemental Figure 1 (supplemental material available online with this article; doi:10.1172/ JCI37613DS1). The structure of Gamitrinib is combinatorial ( Figure 1A ) and contains a benzoquinone ansamycin backbone derived from the Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) (14) , a linker region on the C17 position, and a mitochondrial targeting moiety, either provided by 1 to 4 tandem repeats of cyclic guanidinium (27) (Gamitrinib-G1-G4) or triphenylphosphonium (28) (Gamitrinib-TPP-OH) ( Figure  1A ). By molecular dynamics simulation, the 17-AAG portion of Gamitrinib is predicted to make contacts with the Hsp90 ATPase pocket, whereas the mitochondriotropic guanidinium module is excluded from the binding interface, pointing outside of the ATPase pocket toward the solvent ( Figure 1B, top panel) . In the predicted docking structure, the binding arrangement of Gamitrinibs to Hsp90 closely follows that of GA (29), with root mean We next carried out 2 experiments to test whether the addition of a mitochondriotropic moiety reduced the ability of the 17-AAG backbone to bind Hsp90 and block its chaperone function. In previous studies, modifications of the C17 position of GA or 17-AAG did not affect inhibition of the chaperone ATPase cycles. Consistent with this, increasing concentrations of GA effectively competed with GA affinity beads for binding to Hsp90 in a tumor cell lysate (Figure 2A, left panel) . Similarly, Gamitrinib-G4 displaced Hsp90 from GA affinity beads, albeit less efficiently than GA in this assay (Figure 2A, right panel) . Conversely, increasing concentrations of both unconjugated 17-AAG and Gamitrinib-G4 capably inhibited Hsp90 chaperone activity ( Figure 2B ), using a purified client protein assay, i.e., Chk1 reconstitution assay (30) . We next asked whether the combinatorial design of Gamitrinibs allowed their accumulation in isolated tumor mitochondria. For these experiments, we used a spectrophotometric approach coupled to gradient density ultracentrifugation of cellular extracts for isolation of purified mitochondria ( Figure 2C ). In preliminary studies, we found that at a drug concentration of 0.2 M, unconjugated 17-AAG exhibited 2 peaks of absorption at 338 nm (absorption, 2.448) and 533 nm (absorption, 0.182), whereas peak absorption for Gamitrinib-G4 was at 338 nm (absorption, 2.124) and 543 nm (absorption, 0.138), respectively. Thus, an absorbance at 338 nm was chosen for all subsequent detection studies of Gamitrinibs. Using these experimental conditions, Gamitrinib-G4 was readily detected at a 1-1.5 M interface, corresponding to isolated mitochondria after gradient density ultracentrifugation (Figure 2, C and D) . In contrast, 17-AAG did not localize to the mitochondrial interface as compared with untreated samples (Figure 2 , C and D) in agreement with previous observations (22) . Using a similar approach, all Gamitrinibs accumulated comparably in isolated tumor mitochondria, regardless of the structure or composition of their mitochondriotropic moieties ( Figure 2E ).
Gamitrinibs induce sudden mitochondrial permeability transition. When added to isolated tumor mitochondria, Gamitrinibs caused immediate loss of inner mitochondrial membrane potential, all with comparable efficiency, regardless of their different mitochondriotropic moieties ( Figure 3A) . In contrast, unconjugated Hsp90 inhibitors, including GA, 17-AAG, or 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG), did not affect mitochondrial membrane potential ( Figure 3A) . Next, we asked whether this response was specific for inhibition of Hsp90 chaperone activity inside mitochondria. Consistent with the data presented above, Gamitrinibs (Gamitrinib-G4 or -TPP-OH) suddenly depolarized tumor mitochondria, and this reaction was partially reversed by cyclosporine A (CsA), an inhibitor of the immunophilin CypD ( Figure 3B ). In contrast, treatment of tumor mitochondria with the mitochondriotropic moieties of Gamitrinbs, tetraguanidinium (TG-OH) or TPP-OH plus unconjugated 17-AAG or GA had no effect on mitochondrial membrane potential, with or without CsA ( Figure 3B ).
Loss of mitochondrial membrane potential followed by rupture of the outer membrane and release of cytochrome c are hallmarks of mitochondrial permeability transition (21) and the molecular prerequisites for the initiation of the intrinsic pathway of apoptosis (21) . To further test this model, we examined the ability of Gamitrinibs to induce cytochrome c release from isolated tumor mitochondria. In these experiments, all Gamitrinibs induced rapid (20 minute) discharge of mitochondrial cytochrome c in the supernatant, whereas unconjugated 17-AAG was ineffective ( Figure 3C ). Because Gamitrinib-induced loss of mitochondrial membrane potential was sensitive to CsA ( Figure 3B ), we next asked whether pharmacologic inhibition of CypD prevented the accumulation of the compound(s) in mitochondria. Gamitrinib-G4 readily accumulated in isolated tumor mitochondria, within the same time interval of induction of organelle permeability transition ( Figure  3D ), in agreement with the data presented above (Figure 2 , C-E). In these experiments, preincubation of isolated mitochondria with CsA, under the same conditions used to antagonize permeability transition ( Figure 3B ), did not reduce Gamitrinib accumulation in mitochondria ( Figure 3D ).
Additional derivatives of 17-AAG as well as purine-and isoxazole resorcinol-based Hsp90 antagonists (Supplemental Figure 2) have been recently developed, with promising anticancer activity in preclinical studies (25) . Therefore, it was of interest to test whether these GA-modified or non-GA-based Hsp90 antagonists affected mitochondrial integrity. Gamitrinib-G4 induced sudden and complete discharge of cytochrome c from tumor mitochondria ( Figure  3E ), in agreement with the data above. In contrast, increasing concentrations of 17-AAG, hydroquinone derivative of 17-AAG (IPI-504), purine analog (BIIB021), or isoxazole (NVP-AUY922) Hsp90 inhibitors (25) had no effect on cytochrome c release ( Figure 3E ).
Induction of mitochondrial apoptosis by Gamitrinibs. A 3-hour exposure of lung adenocarcinoma H460 cells to Gamitrinib-G3 or -G4 was sufficient to produce concentration dependent (IC 50 ~0.5 μM) and complete loss of cell viability ( Figure 4A , left panel) in the tumor cell population. Within this time frame, Gamitrinib-G1 or 17-AAG had no effect and Gamitrinib-G2 or Gamitrinib-TPP-OH had intermediate activity ( Figure 4A , left panel). By 24 hours, all Gamitrinibs had comparably killed the entire tumor cell population, whereas 17-AAG had only partially reduced cell viability or cell proliferation ( Figure 4A , right panel). As Gamitrinibs all comparably induce membrane depolarization of isolated mitochondria ( Figure 3A ), these data suggest that the Gamitrinib-G4 and -G3 moieties provide more efficient intracellular drug uptake, as compared with Gamitrinib-G1 and -G2 structures in vivo.
We next studied the cell death phenotype induced by Gamitrinibs. Treatment of H460 cells with Gamitrinib-G4 resulted in rapid loss of mitochondrial membrane potential in the whole tumor cell population, pronounced effector caspase activity, and cell death consistent with genuine mitochondrial apoptosis (Figure 4B) . In contrast, vehicle alone had no effect on mitochondrial integrity or cell viability ( Figure 4B ). Proapoptotic Bcl-2 family proteins regulate mitochondrial cell death, in particular permeabilization of the outer membrane (21) . Therefore, we next asked whether Gamitrinib-induced tumor cell killing was dependent on Bax, a multidomain proapoptotic Bcl-2 protein required for many cell death responses (31) . In these experiments, Gamitrinib-G4 comparably induced concentration-dependent killing of wild-type or Bax -/-colorectal cancer HCT116 cells (Figure 4C) . Consistent with these data, Gamitrinib-G4 exhibited a broad spectrum of anticancer activity, and comparably killed a molecularly and genetically heterogeneous panel of tumor cell types, representative of epithelial and hematologic malignancies (Table 1) . In contrast, exposure of these cells to the mitochondriotropic moiety (TG-OH) plus unconjugated 17-AAG had no effect on cell viability (Table 1 ). Mitochondriotoxic mechanism of action of Gamitrinibs. Current Hsp90 inhibitors predominantly cause cell cycle arrest in most tumor cell types, followed by a variable degree of apoptosis after a prolonged drug exposure of 48-72 hours. To test whether Gamitrinibs had a similar mechanism of action, we used breast adenocarcinoma SKBr3 cells, which are considered sensitive to Hsp90 inhibition. Gamitrinib-G4, Gamitrinib-TPP-OH, or unconjugated 17-AAG all resulted in comparable reduction of metabolic activity in SKBr3 cells by 48 hours and throughout a 96-hour interval after treatment ( Figure 5A ). However, most SKBr3 cells treated with 17-AAG were still alive after 72 hours, as shown using Trypan blue exclusion and light microscopy ( Figure 5B ). In contrast, Gamitrinibs were cytotoxic, and a 24-hour treatment was sufficient to cause nearly complete killing of the entire tumor cell population ( Figure 5B ). When analyzed in a model of long-term tumorigenicity, a brief (4-hour) exposure of H460 cells to Gamitrinib-G4 completely abolished colony formation in soft agar after a 2-week incubation ( Figure  5C ). In contrast, 17-AAG had no effect on tumorigenicity under the same conditions, and vehicle alone did not decrease H460 colony formation in soft agar ( Figure 5C ).
A hallmark of Hsp90 inhibition by conventional small molecule antagonists is the degradation of client proteins in the cytosol, with concomitant upregulation of Hsp70 chaperone levels. Consistent with this, treatment of cervical carcinoma HeLa cells with 17-AAG resulted in efficient loss of Hsp90 client proteins, Akt and Chk1 (14) , and increased expression of Hsp70 (32) , as analyzed by Western blotting ( Figure 5D ). At variance with this phenotype, incubation of HeLa cells with Gamitrinib-G4 had no effect on the levels of Hsp90 client proteins in the cytosol and did not result in upregulation of Hsp70 levels ( Figure 5D ).
Previous studies have shown that mitochondrial Hsp90 chaperones physically associate with the permeability pore component, CypD (21) , and prevent its opening by a protein folding mechanism that antagonizes the initiation of cell death. Consistent with this model, siRNA silencing of CypD in H460 cells ( Figure 5E , inset) markedly attenuated Gamitrinib-G4-induced tumor cell killing ( Figure 5E ). In contrast, a nontargeted siRNA was without effect (Figure 5E , inset) and 17-AAG did not reduce H460 cell viability within the same time interval in the presence or absence of CypD ( Figure 5E ). Collectively, these data demonstrate that Gamitrinibs exhibit what we believe to be a unique, mitochondriotoxic mechanism of action, which involves CypD induction of organelle permeability transition, without affecting global Hsp90 homeostasis outside of mitochondria.
Selectivity of Gamitrinib anticancer activity. Because mitochondria of most normal tissues do not contain Hsp90 chaperones, it was of interest to test whether Gamitrinibs were selective anticancer agents. Exposure of normal mitochondria isolated from WS-1 human fibroblasts to Gamitrinib-G4 or 17-AAG induced only a modest decrease in mitochondrial membrane potential in the presence or absence of CsA ( Figure 6A ). Similarly, Gamitrinibs did not induce discharge of cytochrome c from normal mitochondria ( Figure 6B ). As control, mitochondria isolated from HeLa cells were nearly completely depleted of cytochrome c after treatment with Gamitrinib-G1 but not 17-AAG ( Figure 6B ). Validating the specificity of these results, Gamitrinib-G4 readily accumulated in isolated normal mouse liver mitochondria, and this response was also unaffected by CypD inhibition with CsA ( Figure 6C ). Similar to the phenotype observed with tumor mitochondria, nontargeted 17-AAG did not accumulate in normal mitochondria ( Figure 6C ). Consistent with this inability to induce mitochondrial permeability transition in normal cells, concentrations of Gamitrinib that readily killed tumor cell types did not cause cell death of normal primary cell types, including bovine aortic endothelial cells or intestinal epithelial cells, and only modestly reduced the viability of normal human foreskin fibroblasts or human umbilical vein endothelial cells ( Figure 6D) . Similarly, comparable concentrations of 17-AAG had no effect on the viability of the various normal human cells tested ( Figure 6D ).
Gamitrinib inhibition of tumor growth in vivo.
Systemic administration of Gamitrinib-G4 to mice inhibited the growth of established human leukemia (Supplemental Figure  3A) , breast (Supplemental Figure  3B) , and lung ( Figure 7A ) xenograft tumors in vivo. In contrast, comparable concentrations of 17-AAG had no effect on human lung cancer growth in mice ( Figure 7A , top panel). Gamitrinibs carrying different mitochondriotropic moieties, i.e., Gamitrinib-G1 or -TPP-OH, also comparably inhibited lung cancer growth in vivo ( Figure 7A , bottom panel). Tumors harvested from Gamitrinib-treated animals exhibited extensive apoptosis in situ ( Figure  7B ) and discharge of cytochrome c in the cytosol ( Figure 7C ), suggestive of treatment-related mitochondrial dysfunction in vivo. At the concentrations used, the various Gamitrinibs did not cause significant animal weight loss throughout the treatment ( Figure 7D ). For preliminary toxicology experiments, organs, including brain, small and large intestine, heart, spleen, liver, pancreas, stomach, lung and kidneys, were collected from mice in the various treatment groups and analyzed histologically. In these studies, organs harvested from Gamitrinib-treated animals were histologically unremarkable compared with the vehicle group, with no changes in general architecture and no evidence of inflammation or liver steatosis (Supplemental Figure 4) .
Discussion
In this study, we reported the combinatorial structure and activity of Gamitrinibs, which we believe to be the first class of small molecules engineered to selectively target a compartmentalized Hsp90 network in tumor mitochondria (22) . Gamitrinibs efficiently accumulate in mitochondria, trigger sudden and irreversible organelle permeability transition, and induce exceedingly fast (~1 hour) and complete tumor cell killing by apoptosis. In turn this results in inhibition of tumor growth in vivo, with no detectable toxicity for normal cells or tissues. Differently from current Hsp90 antagonists, Gamitrinibs exhibit what we believe to be a novel mechanism of action, exclusively centered on induction of mitochondrial dysfunction, i.e., mitochondriotoxic, and do not affect global Hsp90 homeostasis outside of mitochondria. For these combined properties, we believe Gamitrinibs are novel, attractive anticancer agents, suitable for human testing.
New strategies for cancer drug discovery are urgently needed to remedy the high cost, low yield, and high risk of failure of traditional, target-centric drug discovery (7). An integrated, pathwayoriented approach that aims at cancer networks in their globality, instead of individual genes in isolation (5), has recently emerged as a potentially attractive alternative to drug discovery (11) . However, this may still not be sufficient to capture the complexity of cancer networks, as these pathways are not randomly assembled in tumor cells but compartmentalized in specialized, semiautonomous microenvironments (33) . The data presented here, based on the combinatorial delivery of a well-known Hsp90 inhibitory moiety (17-AAG) (14) to a specialized compartment (mitochondria) (22) , demonstrate that incorporating subcellular targeting in drug design is not only feasible but also leads to the generation of effective agents with specificities and mechanisms of action, which we believe to be novel.
Similar to the mitochondriotropic design of Gamitrinibs, the idea of manipulating mitochondrial homeostasis (21) for novel cancer therapeutics has been aggressively pursued (34) . Small molecule modifiers of pro-or antiapoptotic Bcl-2 family proteins that shift the balance in mitochondrial outer membrane permeability and trigger the release of apoptogenic proteins in the cytosol (35) have now reached the clinic (34). However, Gamitrinibs are different from these agents, as they directly target a potential upstream step in mitochondrial permeability transition, resulting in immediate depolarization of the inner membrane and sudden collapse of organelle integrity. Because this pathway is unaffected by proapoptotic regulators of outer membrane permeability, e.g., Bax (35) , Gamitrinibs may be less sensitive to mechanisms conferring resistance to Bcl-2 modifier drugs (34), including upregulation of antiapoptotic Mcl-1 (36) or activation of parallel pathways of cytochrome c release (37) .
The molecular requirements of mitochondrial permeability transition as a pathophysiological antecedent of apoptotic cell death have not been completely elucidated (21) . Molecules that had long been held as essential constituents of a permeability transition pore, including the voltage-dependent anion channel (VDAC) (38) or the adenine nucleotide translocator (ANT) (39) , turned out to be dispensable for mitochondrial cell death. Conversely, there is agreement that the matrix immunophilin CypD is essential to execute mitochondrial permeability transition, especially in response to certain cell death stimuli, for instance, Ca 2+ overload or oxidative stress (40) (41) (42) . Here, Gamitrinib-induced anticancer activity was dependent on CypD function, with respect to both depolarization of the inner membrane and tumor cell killing. Whether this reflects a role of CypD in an organized permeability transition pore (21) or its dynamic assembly in clusters of unfolded mitochondrial proteins that mediate conductance across the mitochondrial membrane (43) remains to be determined. However, the latter model better explains a cytoprotective function of mitochondrial Hsp90 chaperones (22) , which may involve refolding of unfolded protein clusters generated by oxidative stress, with suppression of CypD-dependent pore opening (43) . In this context, inhibition of mitochondrial chaperone activity by Gamitrinibs would acutely remove this steady-state cytoprotective mechanism, unrestraining an organelle unfolded protein response that culminates with CypD-dependent permeability transition and irreversible mitochondrial collapse (43) . Although this cell death pathway has the hallmarks of mitochondrial apoptosis, it was only minimally affected by pharmacologic caspase inhibitors (data not shown), thus suggesting that Gamitrinib anticancer activity may also escape compensatory mechanisms downstream of mitochondria, typically involving upregulation of inhibitor of apoptosis (IAP) proteins (44) .
Several small molecule Hsp90 antagonists based on the structure of GA (17-AAG, IPI-504) or purine or resorcinol (BIIB021, NVP-AUY922) have been recently developed (25) . As shown here, none of these agents, even at high concentrations, affected mitochondrial integrity, as quantified by analysis of mitochondrial inner membrane potential or cytochrome c release. This likely reflects their inability to cross the mitochondrial membrane(s) or accumulate in the organelle, which was anticipated in earlier fluorescence localization studies with FITC-coupled 17-AAG (22) . In the absence of mitochondrial targeting, the different Hsp90 antagonists primarily induce a cytostatic phenotype in tumor cells (45, 46) , characterized by G 1 and/or G 2 /M cell cycle arrest. This is due to loss of proliferation-associated Hsp90 client proteins in the cytosol (14) and a variable, but always partial degree of apoptosis after protracted drug exposure. Cell-type specific differences in the sensitivity to GA-or non-GA-based Hsp90 antagonists have also been reported that may further affect their anticancer activity (45, 46) . Conversely, mitochondrial targeting radically changed the activity profile of these agents, e.g., 17-AAG, as Gamitrinibs exclusively exhibited a cytotoxic phenotype, induced nearly complete tumor cell killing within 1 hour of treatment, and showed comparable efficacy against a broad spectrum of tumor cell types, regardless of molecular or genetic makeup. Further reinforcing their unique mechanism of action, Gamitrinibs did not affect the homeostatic functions of Hsp90 in the cytosol, leaving untouched the levels of various client proteins, without upregulation of Hsp70 expression. These observations reaffirm the selectivity of Gamitrinibs solely for the mitochondrial pool of Hsp90 (22) and suggest that this pathway may be unaffected by a third tier of compensatory mechanisms that are invariably induced by nontargeted Hsp90 inhibitors, including upregulation of cell survival molecules, for instance, Hsp70 (47), activation of oncogenic kinases (48) , and paradoxical enhanced metastatic dissemination in vivo (49) .
The mechanism of action of Gamitrinibs is also distinct from that of the peptidomimetic Shepherdin (50), which also inhibits Hsp90 ATPase activity and accumulates in mitochondria (22) . Modeled on the binding interface between Hsp90 and the client protein, survivin (50), Shepherdin produces a dual phenotype of degradation of Hsp90 client proteins in the cytosol (50) as well as induction of mitochondrial permeability transition (22) . These data suggest that the cytosolic transfer of Shepherdin may be long enough to mediate inhibition of Hsp90 activity in the cytosol followed by mitochondrial accumulation. Conversely, 2 structurally unrelated small molecule moieties, TPP-OH (28) or tandem repeats of cyclic guanidinium (27) , mediated fast mitochondrial targeting of Gamitrinibs, which prevented inhibition of cytosolic Hsp90. These data have important practical implications for drug delivery in vivo. For their rapid localization to mitochondria, Gamitrinibs are expected to escape sequestration by the high concentrations of Hsp90 in the cytosol (1%-2% of total cellular protein content), which may otherwise decrease the efficiency of intramitochondrial accumulation.
Despite their ability to disrupt a fundamental mechanism of mitochondrial integrity (21) , Gamitrinibs are well tolerated in vivo and have no effect on mitochondrial permeability transition of various normal cell types in culture. Considerably more work is needed to establish the full toxicity profile of these agents in vivo, but this observed nontoxicity may reflect the nearly exclusive presence of Hsp90 chaperones in mitochondria of tumors but not most normal tissues in vivo (22) . This differential localization implies a broad exploitation of a cytoprotective mechanism ideally suited to favor cellular adaptation to noxious environments, in particular high levels of oxidative stress, which is invariably associated with tumor growth. Consistent with this model, mitochondrial TRAP-1 (20) has been recently implicated in protection from apoptosis induced by oxidative stimuli (51, 52) . Although mitochondrial chaperones have been detected in certain normal tissues, for example, brain and testis, in which enhanced cytoprotection may be required for normal homeostasis, their affinity for ATPase pocket antagonists is likely 100-fold lower than that of tumor-associated Hsp90, thus adding to a potentially favorable therapeutic window of Gamitrinibs (53) .
In summary, we have developed what we believe to be a novel, combinatorial drug design for the delivery of pathway inhibitors, i.e., Hsp90 ATPase antagonists (14) , to specialized subcellular compartments. This drug engineering paradigm is cost-effective, amenable to further chemical optimization, and broadly applicable to structurally unrelated Hsp90 antagonists (25) and mitochondriotropic moieties. Although applied to the Hsp90 network, a similar approach could be also envisioned to selectively target other compartmentalized cancer networks (33) . Functionally, the first products of this combinatorial approach, i.e., Gamitrinibs, exhibited radically different properties compared with their parental, nontargeted Hsp90 inhibitors, with respect to specificity, profile of anticancer activity, and mechanism of action. Therefore, such compartmentalized, pathway-oriented drug discovery can unlock novel properties In situ internucleosomal DNA fragmentation as shown by TUNEL staining. At the end of treatment, tumors were harvested from vehicle-or Gamitrinibtreated animals, fixed in formalin, embedded in paraffin, and sectioned. TUNEL staining was performed with the ApopTag Plus Peroxidase In situ Apoptosis Detection Kit (Chemicon), according to the instruction manual, as described previously (56) . Images were captured using an Olympus microscope with an on-line charge-coupled device camera at ×400 magnification (necrotic regions were excluded from the analysis). For quantification, TUNEL-positive cells were counted in 10 independent areas of a ×400 magnification field (10 fields/each group).
Histology. Animals in the vehicle or Gamitrinib group were euthanized at the end of the experiment, and organs, including brain, colon, heart, kidney, liver, lung, pancreas, small intestine, spleen, and stomach, were collected, fixed in formalin, and embedded in paraffin. Sections (5 μm) were put on high-adhesive slides, stained with H&E, and analyzed by light microscopy.
Statistics. Data were analyzed using the unpaired Student's t test on a GraphPad software program (Prism 4.0). All of the statistical tests were 2 sided. A P value of 0.05 was considered to be statistically significant.
